Skip to main content
. 2021 Nov 29;13(23):6003. doi: 10.3390/cancers13236003

Table 3.

A skew towards immunosuppression in the tumour microenvironment can drive resistance to immune checkpoint inhibitors.

Event Impact on the Tumour Microenvironment
Increased AXL receptor tyrosine kinase (AXL) expression Increases regulatory T cells, MDSCs and M2 macrophages [185]
Increased Wnt signalling Decreases tumour infiltrating lymphocytes [185]
Loss of Phosphatase and tensin homolog (PTEN) Induces vascular endothelial growth factor (VEGF) production and reduces T cell infiltration [176,185]
Loss of functional beta 2 microglobulin Dysfunctional CD8+ T cells [175,188]
Hypoxia Dysfunctional CD8+ T cells [184,187]
Upregulation of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) Dysfunctional T helper 1 (Th1) cells and reduced cytokine expression [189,190]
Reduced expression of absent in melanoma 2 (AIM2) Decreases inflammation [181]
Reduced expression of poliovirus receptor-related immunoglobulin domain containing protein (PVRIG) Dysfunctional CD8+ T cells [181]
Increased expression of mannosidase alpha class 2A member 1 (MAN2A1) Altered Th1/T-helper 2 (Th2) axis towards Th2 expression [181]